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Abstract
Background: Sufficiently detailed abstracts of randomized controlled trials (RCTs) are important, because readers
often base their assessment of a trial solely on information in the abstract. We aimed at comparing reporting
quality of RCTs in HIV/AIDS medicine before and after the publication of the 2008 CONSORT extension for abstracts
and to investigate factors associated with better reporting quality.
Methods: We searched PubMed/Medline for HIV/AIDS RCTs published between 2006–07 (Pre-CONSORT) and 2014–15
(Post-CONSORT) in 40 leading general medicine and infectious diseases journals. Two investigators extracted data and
scored abstracts. The primary outcome was the adjusted mean number of items reported among the 17 required.
Proportions of abstracts reporting each of 17 items were considered as secondary outcome. The adjustment was done
for journal field, CONSORT endorsement, abstract format, type of intervention, journal impact factor and authorship.
This study received no funding.
Results: The adjusted mean number of reported items was 7.2 (95 % CI 6.6–7.7) in pre-CONSORT (n = 159) and 7.8
(95 % confidence interval [CI] 7.3–8.4) in post-CONSORT (n = 153) (mean difference 0.7; 95 % CI 0.1–1.2). Journal high
impact factor (adjusted incidence rate ratio 2.16; 95 % CI 1.83–2.54), abstract with 13 authors or more (1.39; 95 % CI 1.
07–1.79) and non-pharmacological intervention (1.19; 95 % CI 1.03–1.37) were independent factors for better reporting
quality. There were significant improvements in reporting on participants, randomization, outcome results, registration
and funding; regression for author contact; and no change for other items: title, design, interventions, objective,
primary outcome, blinding, number randomized, recruitment, number analyzed, harms and conclusions.
Conclusions: After the publication of the CONSORT extension for abstracts, the reporting quality of HIV/AIDS RCT
abstracts in general medicine and infectious diseases journals has suboptimally improved. Thus, stricter adherence to
the CONSORT for abstract are needed to improve the reporting quality of HIV/AIDS RCT abstracts.
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Background
Randomized controlled trials (RCTs) which are designed
to provide the best quality of evidence required for
health care decisions [1, 2] should ideally be reported ac-
cording to pre-defined standards. Most readers of arti-
cles reporting RCT usually start by making an initial
assessment of the interest of the article after reading the
content of the abstract, which subsequently guides the
decision on whether to read the entire article or not [3].
With an overwhelming day-to-day workload, the continu-
ous availability of large volumes of new scientific publica-
tions, limited access to many full-text articles (particularly
in resource limited settings) [4], many health professionals
tend to make recourse to information on abstracts to take
health care decisions [3]. As such abstracts of trials re-
ported in journals should contain sufficiently accurate and
clear information that permits the reader to get a good
synopsis of the findings of the trial [5]. Formerly, there
was no standardized method of reporting RCT and this
created many discordances in the reporting of RCTs.
These discrepancies, stimulated the establishment of the
Consolidated Standards of Reporting Trials (CONSORT)
statement, the first of which was published in 1996 and re-
vised in 2001 [6, 7], which aimed at “standardizing” and
improving the way RCTs are reported [8]. In order to
avoid inconsistencies between the content of the abstract
and the full text of the article, as was seen in many RCT
reports, an extension to the CONSORT statement was
published in 2008, which provided a list of essential items
to be included for reporting of abstracts of RCTs [9]. This
statement comprises seventeen items distributed in eight
sections which include: the title, authors contact details,
trial design, methods (participants, interventions, object-
ive, outcomes, randomization, blinding), results (numbers
randomized, recruitment, numbers analyzed, outcome,
harms), conclusions, trial registration and funding [9].
Following the publication of this CONSORT extension
for abstract reporting, studies to assess the quality of ab-
stract reporting in general medicine journals and other
specific fields of medicine have been done. These studies
have shown that there is substantial room for improvement
in the adherence to these reporting guidelines [10–19].
However, as concerns RCTs in HIV/AIDS medicine,
there are limited studies investigating the impact of
CONSORT extension for abstract reporting checklist. In
this field of HIV/AIDS where guidelines to tackle the
pandemic are continually changing, adherence to this
statement is particularly important, most especially as
HIV/AIDS disproportionally affects resource limited
settings (mainly sub-Saharan African countries) where
most of the RCTs are done but most of health profes-
sionals do not have access to full-text articles required
for health care decision making. We therefore, in the
present study, using abstracts of the periods before and
after the publication of CONSORT extension for abstracts,
aim to first of all compare the overall reporting quality of
RCTs in HIV/AIDS medicine published in general medi-
cine and infectious diseases journals, and secondly deter-
mine the factors associated with better reporting quality.
Methods
Design
We conducted a systematic review of abstracts published
in 2006, 2007, 2014 and 2015 in 20 leading general medi-
cine and 20 leading infectious diseases journals based on
2014 impact factor.
Data sources
We conducted a MEDLINE/PubMed search of all RCTs
published in the years 2006–2007 and 2014–2015. The
search strategy used MeSH terms like “randomized con-
trolled trial” as publication type, journal names and HIV
and AIDS as terms in title/abstract. We limited search
for the following periods: (2006/01/01 to 2007/12/31 and
2014/01/01 to 2015/12/31). The choice of the time limit
of 2014 and 2015 was arbitrary and based on the fact
that 6 years after the publication of the first CONSORT
statement for abstracts in 2008, is sufficient time for re-
searchers to have become versed with the recommen-
dations. Other types of articles (editorial, case reports,
comment, observational study, review, meta-analysis and
letters) were excluded. Searches were done regularly
during the study period and the last one was conducted
on February 26, 2016 as could be seen presented in
Additional file 1.
Studies selection
RCT abstracts where interventions were provided to
HIV-infected patients were selected. These abstracts were
included when participant allocation to interventions was
described by the terms “random”, “randomly allocated”,
“randomized”, “randomization” or another word in the
abstract suggesting that participants were randomly
distributed between the trial arms. We considered jour-
nals as CONSORT statement endorser if they refer-
enced CONSORT statement in their ‘Instruction to
authors/Submission guidelines’ or if they reference as
endorser in the CONSORT webpage (http://www.consort-
statement.org/about-consort/consort-endorsement/consort-
endorsers—journals/). Two reviewers independently se-
lected abstracts.
Data extraction and covariates
Data extraction was independently done by two reviewers
using a pre-made and pretested data extraction form in
compliance with the items of the recommendations of the
evaluation of RCTs using the CONSORT for abstracts [9].
Each question had a ‘yes’ or ‘no’ response for each item
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indicating whether the authors had reported it or not.
Agreement between the two reviewers was measured
using the Kappa statistic [20] and discrepancies were
resolved by discussion among the authors or by arbitra-
tion of a third author. Other information collected from
journals other than the CONSORT abstracts items,
were journal name, type of abstract format (IMRAD
[introduction, method, results and discussion] or eight-
heading [objective, design, setting, participants, interven-
tion, main outcome measure, results and conclusions] or
one-block), type of interventions in the trial (pharmaco-
logical or non-pharmacological), number of authors,
publication on behalf of a research collaboration group,
and journal field (infectious diseases or general medicine).
Main outcomes definition
The primary outcome was the number of items reported
in each selected abstract. The secondary one was the pro-
portion of abstracts reporting each of 17 recommended
items.
Statistical analysis
IBM Statistical Package for Social Science (IBM SPSS)
version 23.0 for Windows (IBM Corp. Released 2014.
IBM SPSS Statistics for Windows, Version 23.0. Armonk,
NY: IBM Corp.) was used to code, enter and analyze data.
Categorical variables were expressed as numbers with
percentages (%). Continuous variables were expressed
as means with standard deviation.
We expressed the number of items for each year as
mean (standard deviation [SD]). We estimated mean dif-
ferences using the independent two-sample T-test for
unadjusted means and the generalized estimation equa-
tions (GEEs) for adjusted means [21]. All these mean
differences were reported with 95 % confidence intervals
(95 % CI). The χ2 was used to compare compliance with
the 17 items of CONSORT extension for abstracts
between pre-CONSORT and post-CONSORT for ab-
stracts publication. This was also done using GEE for
adjusted analysis. We reported measures of association
as odd ratios (OR) for univariate analyses and as ad-
justed odds ratios (aOR) for multivariate analyses both
with their 95 % CI. A p-value < 0.05 was considered sta-
tistically significant.
Incidence rate ratios (IRRs) were computed to identify
factors associated with better reporting in 2014–15 ab-
stracts using GEE. For this analysis, Poisson distribution
and unstructured correlation matrix were assumed. Uni-
variate and multivariate analyses were conducted.
For GEE, adjustments were made for CONSORT endor-
ser journal (yes/no), abstract format (IMRAD/8-heading/
one-block), publication on behalf of a group (yes/no),
number of authors (≤6/7–12/≥ 13), and journal field
(general medicine/infectious diseases). Journal name has
been used as grouping factor due to fact that they can
similarity in articles published in the same journal. The
adjustment was done for abstract format because there
are previous studies reporting relationship between ab-
stract format and quality reporting [15, 22]. The adjust-
ment was also done for number of authors and publication
on behalf a group because it was reported an associ-
ation with higher quality of work with number of col-
laborators [23, 24].
Results
General characteristics of selected abstracts
Our search yielded 444 articles of which 95 were pub-
lished in 2006, 103 in 2007, 140 in 2014 and 106 in 2015.
One hundred and thirty-two abstracts did not meet our
inclusion criteria, hence were excluded. We therefore
included 76 abstracts from 2006, 83 from 2007 (2006–07,
n = 159), 81 from 2014 and 72 from 2015 (n = 153) as
shown in the flow diagram (Fig. 1).
Fig. 1 Flow chart of included studies
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The inter-observer agreement value was 0.86 for ab-
stract selection, 0.71 for overall rating of abstract report-
ing quality, and varied between 0.74 and 0.98 for each
items of CONSORT for abstracts.
All articles came from 19 of 40 journals included in
search strategy. Interventions were pharmacological/
vaccine in 76 % (238/312) of the abstracts. The IMRAD
format was used in 85 % (266/312) of abstracts. Among
all the journals, 84 % of abstracts (262/312) were from
journals which endorsed CONSORT, 80 % (248/312)
were from infectious diseases journals, 63.5 % (198/312)
were published on behalf of a group, and 75 % (233/312)
were published in journals with impact factor less than 10.
The mean number of authors among articles was 12.2
(SD 6.8) (Table 1).
Overall quality of reporting
Only 1 % (2/153) of abstracts reported all items in the
2014–15 period. The mean number of items reported in
2006–07 (6.2; SD = 2.5; Median 6; Range 1–14) differed
significantly from that reported in 2014–15 (7.7; SD = 4.0;
Median 7; Range 1–17), mean difference (MD): 1.6;
95 % CI 0.8–2.3; p <0.001.
In the GEE analysis, after adjusting for covariates among
the type of intervention, journal endorser of CONSORT,
format of abstract, journal field, numbers of authors, jour-
nal impact factor and publication on a behalf of a group,
the adjusted mean number of items reported in 2006–07
(7.2; 95 % CI 6.6–7.7) differed significantly from that
reported in 2014–15 (7.8; 95 % CI 7.3–8.4), adjusted
MD: 0.7; 95 % CI 0.1–1.2; p = 0.015.
Quality of reporting of each item
In univariate analysis, there was improvement from
2006–07 to 2014–15 for ‘title’, ‘trial design’, ‘participants’,
‘objective’, ‘randomization’, ‘blinding’, ‘recruitment’, ‘num-
ber analyzed’, ‘outcome’, ‘conclusion’, ‘trial registration’ and
‘funding’. However, the quality of abstracts decreased for
‘author contact’. After adjustment, the quality of abstract
remained improved for the following items: ‘participants’
(aOR 1.92; 95 % CI 1.05–3.51), ‘randomization’ (p < 0.001),
‘outcome’ of results section (aOR 2.26; 95 % CI 1.17–
4.35), ‘trial registration’ (aOR 8.32; 95 % CI 3.66–10.88)
and ‘funding’ (p < 0.001). From the 2006–07 period to the
2014–15 period, the quality of the item ‘author contact’
decreased (aOR 0.06; 95 % CI 0.03–0.12) (Table 2).
Factors associated with better reporting quality in
2014–2015 abstracts
In univariate analysis, factors associated with better
reporting included publishing in general medicine journal,
publishing in CONSORT endorser journals, structured
abstract (IMRAD or 8-heading), high impact journal,
more than 13 authors and publishing on behalf of a
research collaboration group. In multivariate analysis,
factors independently associated with better reporting
of abstracts in 2014–15 included publishing on non-
pharmacological/vaccine intervention (aIRR 1.19; 95 % CI
1.03–1.37), more than 13 authors (aIRR 1.39; 95 % CI
1.07–1.79) and high journal impact factor (aIRR 2.16;
95 % CI 1.83–2.54) (Table 3).
Discussion
This study aimed to assess, according to the CONSORT
for abstract checklist, the differences in the reporting
quality of abstracts of RCTs in HIV/AIDS medicine pub-
lished in general medicine and infectious diseases jour-
nals before (in the years 2006–07) and after (in the years
2014–15) the publication of the CONSORT extension
for abstracts [9]. Our findings demonstrate that for some
items (participants, randomization, outcome of results
section, trial registration and funding), the reporting
quality of HIV/AIDS RCT abstracts has improved signifi-
cantly in the post-CONSORT era as compared to the pre-
CONSORT era, while for others the quality has remained
unchanged or regressed (authors contact). These re-
sults are consistent with previous studies that have re-
ported inconsistencies and patterns of non-compliance to
the CONSORT for abstracts guidelines in most of
journals [10–19].
The mean number of items reported increased signifi-
cantly from 2006–07 to 2014–15. This is in line with the
average of 3 more items reported in RCT abstracts in
top-tiers of general medicine journals since 2008 as
found in a recent study [19]. High impact factor was
independently associated with more adherence to
CONSORT abstract items as in a study in which high
impact factor is associated with high quality reporting
for CONSORT items [15, 25–30]. Many people and in-
stitutions consider journal impact factor as the reflect
of articles’ quality [31]. High number of authors was
also independently associated with more adherence to
CONSORT abstract items as in previous studies [23, 24].
One can argue that the involvement of a large number of
authors in an article could improve quality. Many authors
would increase the chances that one or more of the au-
thors ensure to the respect of the reporting guidelines.
We also found non pharmacological/vaccine intervention
in trial a factor for better reporting. This finding requires
more investigation to understand this relationship.
As a whole, the reporting of some items improved
significantly over time: more abstracts in 2014–15 as
compared to 2006–07 identified the study as random-
ized in the title, provided details on the trial design,
randomization, blinding, trial registration and funding.
For most abstract elements there was progress in report-
ing even though this was not significant. One of the main
reasons that can explain the improvement of the overall
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reporting quality of abstracts found in our study is the en-
dorsement of the CONSORT statement by most of the
journals surveyed. Indeed, 84 % of articles included in our
analysis were published in journals that endorsed
CONSORT. A systematic review that examined the ef-
fectiveness of the CONSORT statement in journals
that have formally endorsed it concluded that journals’
adoption of CONSORT is associated with improved
reporting of RCTs [8]. Moreover, another study has also
shown that the endorsement of recommendation and ef-
fective implementation of CONSORT guidelines lead to
the improvement of reporting quality of abstracts [12]. In
line with these studies, our findings stress the need to
expand journal endorsement and implementation of the
CONSORT extension for abstracts before manuscript
submission (in journal submission guidelines), during
review process and editorial assessment. Authors should
be required to submit a completed CONSORT checklist
with each manuscript with an emphasis for CONSORT
extension for abstracts [32]; reviewers should assess the
completeness of abstract reporting; and final manuscript
copyediting would surely improve abstract reporting
quality [19].
Despite this overall improvement, the quality of report-
ing of some items remained sub-optimal, consistent with
findings from other studies [10–19]. Poorly reported items
specifically include methods of randomization and alloca-
tion concealment, and blinding. These items are essential
methodological elements which are critical, therefore ad-
equate standardized reporting is indispensable so as to
demonstrate that selection bias was avoided, thereby
allowing unequivocal interpretations of the study findings
[5]. Nevertheless, less abstracts in 2014–15 reported cor-
responding authors’ details (postal and email addresses).
This is a major drawback when readers need to contact
authors for further information on the study. This de-
pends on journal indexing policy, rather than a deficiency








- AIDS 50 (31.4) 20 (13.1) 70 (22.4)
- AIDS Patient Care STDS 2 (1.3) 7 (4.6) 9 (2.9)
- Annals of Internal Medicine 2 (1.3) 2 (1.3) 4 (1.3)
- Archives of Internal Medicine 4 (2.5) 0 4 (1.3)
- BMC Medicine 0 3 (2.0) 3 (1.0)
- British Medical Journal 3 (1.9) 2 (1.3) 5 (1.6)
- Clinical Infectious Diseases 12 (7.5) 8 (5.2) 20 (6.4)
- HIV Medicine 8 (5.0) 4 (2.6) 12 (3.8)
- International Journal of
Antimicrobial Agents
0 1 (0.7) 1 (0.3)
- JAMA Internal Medicine 0 1 (0.3) 1 (0.3)
- Journal of Acquire Immune
Deficiency Syndrome
39 (24.5) 40 (26.1) 79 (25.3)
- Journal of Antimicrobial
Chemotherapy
1 (0.6) 3 (2.0) 4 (1.3)
- Journal of Infectious Diseases 14 (8.8) 10 (6.5) 24 (7.7)
- Journal of the American
Medical Association, The
2 (1.3) 6 (3.9) 9 (2.9)
- Journal of the International
AIDS Society
0 3 (2.0) 3 (1.0)
- Lancet Infectious Diseases,
The
0 20 (13.1) 20 (6.4)
- Lancet, The 14 (8.8) 7 (4.6) 21 (6.7)
- New England Journal of
Medicine, The
6 (3.8) 7 (4.6) 13 (4.2)
- Pediatric Infectious Diseases
Journal, The
0 6 (3.9) 6 (1.9)
- PLoS Medicine 2 (1.3) 3 (2.0) 5 (1.6)
Mean number of authors 11.1 (4.6) 13.3 (8.4) 12.2 (6.8)
- 0–6 19 (12.0) 20 (13.1) 39 (12.5)
- 7–12 97 (61.0) 67 (43.8) 164 (52.6)
- 13 and more 43 (27.0) 66 (43.1) 109 (34.9)
Journal impact factor
- <10 126 (79.2) 107 (69.9) 233 (74.7)
- ≥10 33 (20.8) 46 (30.1) 79 (25.3)
Pharmacological/Vaccine intervention
- Yes 129 (81.1) 109 (71.2) 238 (76.3)
- No 30 (18.9) 44 (28.8) 74 (23.7)
Abstract format
- IMRAD 137 (86.2) 129 (84.3) 266 (85.3)
- Eight-heading 11 (6.9) 14 (9.2) 25 (8.0)
- One-block 11 (6.9) 10 (6.5) 21 (6.7)
CONSORT Endorsers journals
- Yes 137 (86.2) 125 (81.7) 262 (84.0)
- No 22 (13.8) 28 (18.3) 50 (16.0)
Table 1 Distribution of HIV abstracts by year and characteristics
(Continued)
Journal field
- Infectious diseases 126 (79.2) 122 (79.7) 248 (79.5)
- General medicine 33 (20.8) 31 (20.3) 64 (20.5)
Publication on behalf of a group
- Yes 97 (61.0) 52 (34.0) 114 (36.5)
- No 62 (39.0) 101 (66.0) 198 (63.5)
There were no abstract for the following journals included in search strategy:
AIDS Review, The American Journal of Medicine, American Journal of Preventive
Medicine, Annals of Family Medicine, Annals of Medicine, Canadian Medical
Association Journal, Clinical Microbiology and Infection, Cochrane Database of
Systematic Reviews, Current Opinion in HIV and AIDS, Current Opinion in
Infectious Diseases, Emerging Infectious Diseases journal, Eurosurveillance,
Infection and Immunity, Infection Control and Hospital Epidemiology, Journal of
Cachexia Sarcopenia Muscle, Journal of infection, Journal of Internal Medicine,
Mayo Clinic Proceedings, Medicine and Translational Research
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Table 2 Crude and adjusted odds ratios for adherence to the 12 items of the CONSORT statement for HIV/AIDS abstracts in 2014–2015 compared to 2006–2007
Item Criteria Items reported, n (%) Data collection period (2014–15 versus 2006–07)
2014–15 2006–07 Univariate analysisa Multivariate analysisb
n = 153 n = 159 Odds ratio (95 % CI) P Adjusted odds ratio (95 % CI) P
Title Identification of the study as randomized 103 (67.3) 80 (50.3) 2.03 (1.30–3.22) .002 1.57 (0.93–2.65) .090
Author contact Contact details for the corresponding author including both postal
and email addresses
28 (18.3) 110 (69.2) 0.10 (0.06–0.17) < .001 0.06 (0.03–0.12) < .001
Trial design Description of the trial design (eg, parallel, cluster, non-inferiority,
parallel, N-of-1 trial, etc.)
45 (29.4) 29 (18.2) 1.87 (1.10–3.18) .020 1.56 (0.86–2.83) .142
Methods
- Participants Eligibility criteria for participants and the settings where the data
were collected
73 (47.7) 45 (28.3) 2.31 (1.45–3.69) < .001 1.92 (1.05–3.51) .034
- Interventions Interventions intended for each group 142 (92.8) 140 (88.1) 1.75 (0.80–3.82) .154 2.26 (0.99–5.12) .052
- Objective Specific objective or hypothesis 126 (82.4) 115 (72.3) 1.79 (1.04–3.07) .035 1.31 (0.72–2.39) .384
- Outcome Clearly defined primary outcome 70 (45.8) 74 (46.5) 0.97 (0.62–1.51) .889 0.69 (0.39–1.22) .200
- Randomization How participants were allocated to interventions 19 (12.4) 0 Not estimable < .001 Not estimable < .001
- Blinding (masking) Whether or not participants, care givers and those assessing the
outcomes were blinded to group assignment
18 (11.8) 3 (1.9) 6.93 (2.00–24.05) < .001 4.10 (0.81–20.46) .087
Results
- Number randomized Number of participants randomized to each group 64 (41.8) 56 (35.2) 1.32 (0.84–2.09) .230 1.15 (0.69–1.91) .601
- Recruitment Trial status 50 (32.7) 31 (19.5) 2.00 (1.19–3.36) .008 1.48 (0.82–2.68) .192
- Number analyzed Number of participants analyzed in each group 65 (42.5) 40 (25.2) 2.20 (1.36–3.55) .001 1.69 (0.94–3.04) .077
- Outcome For the primary outcome, a result for each group and the estimated
effect size and its precision
65 (42.5) 40 (25.2) 2.20 (1.36–3.55) .001 2.26 (1.17–4.35) .015
- Harms Important adverse events or side-effects 78 (51.0) 75 (47.2) 1.16 (0.75–1.82) .501 1.15 (0.65–2.02) .632
Conclusions General interpretation of the results 118 (77.1) 102 (64.2) 1.88 (1.15–3.10) .012 1.59 (0.92–2.74) .094
Trial registration Registration number and name of trial register 84 (54.9) 38 (23.9) 3.88 (2.39–6.29) < .001 8.32 (3.66–10.88) < .001
Funding Source of funding 34 (22.2) 1 (0.6) 45.14 (6.09–334.48) < .001 Not estimable < .001
CI confidence interval
aChi squared tests
bGeneralized estimation equations with journal as grouping variable: adjustment has been made for journal impact factor (<10 versus ≥ 10), journal field (general medicine versus infectious diseases), CONSORT
endorser journal (yes versus no), abstract format (IMRAD/eight-heading/one-block), type of intervention (pharmacological versus non pharmacological), number of authors (less than 6/7–12/more than 13); expect for














in reporting. In addition, author contact details are more
relevant for conference abstracts, none of which were in-
cluded in this study [5].
Though we found that there has been some improve-
ment in HIV RCT abstract reporting, our study had
some limitations. We not investigated others factors that
can influence reporting quality. These non-investigated
factors include abstract word count, types of utilization
of CONSORT guidelines in the ‘instructions for authors’
section of journals, and awareness of the CONSORT
statement. Furthermore, this study reports on the ad-
equacy of reporting using the CONSORT checklist items,
but the accuracy of reporting cannot be assured because a
comparison of the abstract and the full text was beyond
our scope.
Conclusions
The reporting quality of RCT abstracts in HIV/AIDS
medicine in general medicine and infectious diseases
journals has sub-optimally improved after the publication
of the CONSORT extension for abstracts. This suboptimal
improvement is associated with journal high impact factor,
high number of authors and non-pharmacological/vaccine
intervention in the trial. However, there is still much to do
for improvement to meet the standards of the CONSORT
for abstracts guidelines. Journal endorsement and more
strict adherence to the CONSORT for abstracts standards
by both authors and journal editors will contribute to
better RCT reports in HIV/AIDS medicine. Further re-
searches are necessary to investigate why authors, re-
viewers, journal editors, funders, institutions and readers
not fully adhere to CONSORT guidelines.
Additional file
Additional file 1: Search strategy for HIV RCTs published in 2006–2007
and 2014–2015 in leading general medicine and infectious diseases journals.
(DOCX 14 kb)
Abbreviations
(a)OR: (adjusted) odds ratio; AIDS: Acquired immunodeficiency syndrome;
CI: Confidence interval; CONSORT: Consolidated standards of reporting trials;
GEE: Generalized estimation equations; HIV: Human immunodeficiency virus;
Table 3 Unadjusted and adjusted incidence rate ratios for the total number of CONSORT extension for HIV abstract items reported
Variables Total number of items reported
Univariate analysis Multivariate analysis
Incidence rate ratio (95 % CI) p Adjusted incidence rate ratio (95 % CI) p
Journal field
- General medicine 33.11 (9.72–112.73) < .001 1.19 (1.00–1.41) .052
- Infectious diseases 1
CONSORT endorsement
- Non endorser journals 1
- Endorser journals 11.22 (3.90–32.27) < .001 1.01 (0.85–1.21) .900
Abstract format
- One-block 1
- IMRAD 20.69 (6.94–61.61) < .001 1.11 (0.81–1.51) .524
- Eight-heading 57.81 (14.64–228.23) < .001 1.28 (1.00–1.67) .061
Pharmacological/Vaccine intervention
- Yes 1
- No 0.40 (0.11–1.42) .155 1.19 (1.03–1.37) .015
Journal impact factor
- <10 1
- ≥10 511.06 (186.40–1401.21) < .001 2.16 (1.83–2.54) < .001
Number of authors
- Less than 6 1
- 7–12 3.81 (0.75–19.41) .108 1.18 (0.98–1.48) .140
- More than 13 89.74 (15.30–526.36) < .001 1.39 (1.07–1.79) .013
Publication on behalf of a collaboration research group
- No 1
- Yes 13.09 (3.50–48.97) < .001 0.99 (0.88–1.11) .867
CI confidence interval, CONSORT consolidated standards of reporting trials, IMRAD introduction, methods, results and discussion
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IMRAD: Introduction, method, results and discussion; IRR: Incidence rate ratio;
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